Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Condensed Consolidated Statements of Operations
Net Revenues	$ 52,979	$ 51,337	$ 151,223	$ 158,581
Operating Expenses
Cost of sales (excluding depreciation and amortization)	20,118	15,002	62,617	45,359
Research and development	2,939	4,982	12,318	15,128
Selling, general, and administrative	15,725	14,357	50,621	41,829
Depreciation and amortization	11,358	9,473	33,739	35,048
Cortrophin pre-launch charges	37	195	8,275	195
Total Operating Expenses	50,177	44,009	167,570	137,559
Operating Income/(Loss)	2,802	7,328	(16,347)	21,022
Other Expense, net
Interest expense, net	(2,510)	(3,336)	(6,898)	(10,096)
Other expense, net	(229)	(33)	(335)	(117)
Income/(Loss) Before Benefit/(Provision) for Income Taxes	63	3,959	(23,580)	10,809
Benefit/(provision) for income taxes	371	(64)	4,667	120
Net Income/(Loss)	$ 434	$ 3,895	$ (18,913)	$ 10,929
Basic and Diluted Earnings/(Loss) Per Share:
Basic Earnings/(Loss) Per Share	$ 0.04	$ 0.32	$ (1.58)	$ 0.91
Diluted Earnings/(Loss) Per Share	$ 0.04	$ 0.32	$ (1.58)	$ 0.89
Basic Weighted-Average Shares Outstanding	11,991	11,879	11,953	11,826
Diluted Weighted-Average Shares Outstanding	12,003	12,085	11,953	12,060